Citigroup
ASBP

Citigroup’s Aspire Biopharma ASBP Stock Holding History

Citigroup’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.9K Buy
+62
New +$3.3K ﹤0.01% 5432
2023
Q2 		– Sell
-74
Closed -$935K – 5758
2023
Q1 		$935K Sell
74
-10
-12% -$125K ﹤0.01% 2613
2022
Q4 		$1.03M Sell
84
-23
-21% -$282K ﹤0.01% 2584
2022
Q3 		$1.3M Buy
107
+84
+365% +$1.01M ﹤0.01% 2497
2022
Q2 		$278K Buy
+23
New +$275K ﹤0.01% 3648

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.55B AUM 28.47% 1-Year Est. Return

Citigroup's ASBP Position: Q1 2026 in Review

Citigroup opened a new position in Aspire Biopharma (ASBP) in Q1 2026: 62 shares worth $1.9K. The stake represents ﹤0.01% of the portfolio and ranks #5432 among its holdings. This is a return to the name: Citigroup previously reported a position in ASBP as recently as Q1 2023.

Citigroup first reported a position in ASBP in Q2 2022 and has held it in 5 quarters since. The position peaked at $1.3M in Q3 2022. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

  • Citigroup held 62 shares of Aspire Biopharma worth $1.9K as of Q1 2026.
  • Aspire Biopharma was a new Citigroup position in Q1 2026.
  • Aspire Biopharma made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5432 holding.
  • Citigroup first reported a position in Aspire Biopharma in Q2 2022 and has held it in 5 quarters since.
  • Citigroup's Aspire Biopharma position peaked at $1.3M in Q3 2022.
  • 12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.